May. 15 at 12:17 PM
$INMB INmune Bio publishes MINDFuL trial results in NPJ Dementia
INmune Bio announced that results from its Phase 2 MINDFuL trial in Alzheimer's disease have been published in the peer-reviewed journal NPJ Dementia. The study evaluated the safety, biomarker engagement, and clinical efficacy of XPro in patients with mild Alzheimer's disease characterized by biomarkers of inflammation. In a pre-specified analysis of the protocol-defined Alzheimer's Disease with inflammation subgroup, XPro showed directionally consistent benefit across cognitive, global, functional, behavioral, and biomarker endpoints over 24 weeks, with no amyloid-related imaging abnormalities observed.
The publication discusses how XPro demonstrated consistent positive trends in a pre-specified enriched subpopulation with amyloid-beta positivity and two or more inflammation biomarkers. The paper further highlights the effect sizes up to 0.27 across cognitive, Patient-Reported Outcomes, behavioral and biomarker endpoints, directionally consistent with an XPro treatment effect. These findings support prioritization of the enriched population in future studies to optimize detection of treatment effects.
